Viela Bio (Kidney Transplant) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn more about how the study drug (VIB4920) given with Belatacept (an Immunosuppressive drug) can help stop rejection of a kidney transplant.
What is the Condition Being Studied?
Kidney Transplant

Who Can Participate in the Study?

- Adults 18-70
- Never had a kidney transplant

Age Group

What is Involved?

If you choose to join this study you will:
- Complete physical
- Give blood samples
- Get ECG (looking at electrical activity of the heart)
- Complete follow-up visits for 15 months (every other week for 3 months and then once a month)

Study Details

Full Title
A PHASE 2A SINGLE-ARM, PROSPECTIVE, OPENLABEL PILOT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DUAL COSTIMULATION BLOCKADE WITH VIB4920 AND BELATACEPT FOR PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULTS RECEIVING A KIDNEY TRANSPLANT
Principal Investigator
Kidney/Pancreas Transplant Surgeon
Protocol Number
IRB: PRO00103332
NCT: NCT04046549
Phase
Phase II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698